Berliner Boersenzeitung - OBI Pharma Signs Collaboration and License Agreement with Novartis

EUR -
AED 4.030486
AFN 70.791118
ALL 90.074566
AMD 395.541806
ANG 1.964927
AOA 1007.484738
ARS 1709.287633
AUD 1.63201
AWG 1.97546
AZN 1.861999
BAM 1.9585
BBD 2.210987
BDT 136.668378
BGN 1.946344
BHD 0.414271
BIF 3299.362742
BMD 1.097478
BND 1.415858
BOB 12.860727
BRL 6.357027
BSD 1.097818
BTN 102.579457
BWP 15.508447
BYN 3.293314
BYR 21510.563302
BZD 2.207783
CAD 1.571895
CDF 2517.614101
CHF 0.924624
CLF 0.027877
CLP 1097.653003
CNY 7.315951
CNH 7.318371
COP 3638.533732
CRC 488.063833
CUC 1.097478
CUP 26.346315
CVE 110.420217
CZK 24.38601
DJF 195.480333
DKK 7.47429
DOP 66.373603
DZD 150.492701
EGP 58.992939
ERN 16.462166
ETB 180.183704
FJD 2.521894
FKP 0.830332
GBP 0.833507
GEL 2.842479
GGP 0.830332
GHS 12.887764
GIP 0.830332
GMD 81.213085
GNF 9732.237171
GTQ 8.389793
GYD 229.586453
HKD 8.611195
HNL 29.509616
HRK 7.497929
HTG 143.932982
HUF 367.905233
IDR 20017.993604
ILS 3.593587
IMP 0.830332
INR 102.52785
IQD 1664.193858
IRR 2117093.238936
ISK 136.998381
JEP 0.830332
JMD 174.120794
JOD 0.778126
JPY 174.734362
KES 142.737632
KGS 95.973767
KHR 4472.307077
KMF 491.670042
KPW 987.730332
KRW 1461.938555
KWD 0.342073
KYD 0.914878
KZT 488.221843
LAK 24732.653901
LBP 98306.941749
LKR 365.333561
LRD 184.42252
LSL 18.871442
LTL 3.240566
LVL 0.663854
LYD 7.099818
MAD 10.933771
MDL 20.15524
MGA 4991.903383
MKD 61.586016
MMK 2304.030637
MNT 3958.331441
MOP 8.872312
MRU 44.614495
MUR 52.624309
MVR 16.949422
MWK 1903.532425
MXN 20.41961
MYR 4.516118
MZN 70.129105
NAD 18.871355
NGN 1482.417844
NIO 40.395864
NOK 10.639167
NPR 164.133469
NZD 1.99764
OMR 0.421999
PAB 1.097813
PEN 3.747866
PGK 4.938965
PHP 69.783673
PKR 303.505423
PLN 4.407531
PYG 6871.502711
QAR 4.002226
RON 5.346803
RSD 117.624389
RUB 90.431728
RWF 1624.64675
SAR 4.118015
SBD 8.930222
SCR 15.316084
SDG 660.138046
SEK 11.152843
SGD 1.415115
SHP 0.830919
SLE 25.02637
SLL 23013.563061
SOS 627.367597
SRD 41.028659
STD 22715.572995
STN 24.5346
SVC 9.605415
SYP 14269.405679
SZL 18.868093
THB 37.269798
TJS 10.094235
TMT 3.841172
TND 3.324874
TOP 2.642463
TRY 55.358823
TTD 7.449404
TWD 36.171217
TZS 2913.801126
UAH 49.56174
UGX 4599.339546
USD 1.097478
UYU 44.602698
UZS 13184.172537
VES 1004.742938
VND 28196.946308
VUV 132.865784
WST 3.098488
XAF 655.957
XAG 0.024314
XAU 0.000291907215
XCD 2.965988
XCG 1.978427
XDR 0.775974
XOF 655.957
XPF 119.331742
YER 259.607732
ZAR 18.886161
ZMK 9878.61648
ZMW 22.547874
ZWL 353.387378
SSP 6506.624413
MXV 2.290165
  • CMSD

    -0.1200

    19.81

    -0.61%

  • JRI

    0.0000

    10.77

    0%

  • BCC

    -1.8200

    74.15

    -2.45%

  • CMSC

    -0.2228

    19.53

    -1.14%

  • BCE

    0.2000

    20.34

    +0.98%

  • RIO

    0.0100

    94.17

    +0.01%

  • AZN

    -2.7400

    161.47

    -1.7%

  • GSK

    -1.1800

    48.17

    -2.45%

  • RBGPF

    0.0000

    65

    0%

  • NGG

    0.8800

    75.82

    +1.16%

  • RYCEF

    -0.7300

    19.08

    -3.83%

  • BTI

    -0.4500

    54.4

    -0.83%

  • BP

    0.4700

    43.99

    +1.07%

  • RELX

    -0.0600

    33.18

    -0.18%

  • VOD

    -0.1800

    16.15

    -1.11%

OBI Pharma Signs Collaboration and License Agreement with Novartis
OBI Pharma Signs Collaboration and License Agreement with Novartis

OBI Pharma Signs Collaboration and License Agreement with Novartis

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies.

Text size:

Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes.

This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, and GlycOBI DUO®, and supports OBI's strategy of expanding the global application of its ADC technologies through strategic agreements.

Ya-Chi Chen, Pharm.D., acting Chief Executive Officer of OBI Pharma, Inc., commented: "We are delighted to enter into this agreement with Novartis, a leading pharmaceutical company in innovative oncology drug development with extensive commercialization capabilities. This agreement recognizes the scientific and commercial potential of OBI's proprietary ADC technologies and reflects the value of our differentiated platform. By combining OBI's ADC expertise with Novartis's resources and capabilities, we aim to advance next-generation therapies that could deliver meaningful benefits to patients."

"Engaging with OBI's expertise and technologies in antibody-drug conjugation to create potential ADCs with novel payloads is an important part of our oncology ADC strategy. This collaboration supports our ambition to innovate novel therapies and potentially expand treatment options for patients," said Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis.

Under the terms of the agreement, OBI will receive an upfront payment of USD 30 million and is eligible to receive development, regulatory and commercial milestone payments for a total potential deal value exceeding USD 2 billion. In addition, OBI is eligible to receive tiered royalties on net sales of the licensed products resulting from the collaboration.

About Obrion® ADC Technology

OBI has developed the proprietary Obrion® ADC Technology Platform, which integrates multiple ADC-enabling technologies to support the development of next-generation ADCs. At the core of Obrion® is GlycOBI®, a glycan-based conjugation technology with a flexible, plug-and-play design compatible with a broad range of antibodies, linkers, and payloads, while supporting different drug-to-antibody ratios (DARs).

Powered by OBI's proprietary dual-function enzymatic technology, EndoSymeOBI®, and highly hydrophilic and stable linker technology, HYPrOBI®, GlycOBI® enables the efficient and scalable production of site-specific, homogeneous ADCs under GMP conditions. GlycOBI DUO® further expands the capabilities of the Obrion® platform by enabling next-generation ADC modalities, including dual-payload ADCs.

About OBI Pharma

OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan, with operations in the United States and Australia. The company is focused on developing innovative cancer therapeutics and advancing proprietary antibody-drug conjugate (ADC) technologies to address unmet medical needs and provide new treatment options for patients.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:

Jukka Muhonen
Executive Director, Business Development
OBI Pharma USA, Inc.
email: [email protected]
tel.: +1 617 821 0292

SOURCE: OBI Pharma, Inc.



View the original press release on ACCESS Newswire

(B.Hartmann--BBZ)